The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus

Wang, Lina; Felix, Janine F.; Lee, Joyce L; Tan, Peik Y; Tourgeman, David E; OʼMeara, Anne T.; Amezcua, Charles A.

doi:10.1016/s0090-8258(03)00274-9

Cited by 78 publications

(38 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Now we have demonstrated, in accordance with Wang et al (16), that even uterine leiomyosarcomas express c-KIT, and this expression suggests therapeutic targeting opportunities. Whether uterine malignant stromal tumors will respond to KIT inhibition remains to be established.…”

Section: Discussionsupporting

confidence: 90%

c-Kit Expression in Patients with Uterine Leiomyosarcomas

Raspollini¹,

Amunni²,

Villanucci³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

c-Kit Expression in Patients with Uterine Leiomyosarcomas

Raspollini¹,

Amunni²,

Villanucci³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Hence, a new therapeutic option that can support or can substitute for traditional treatments is needed, and targeted therapy could be a promising approach for the treatment of UES. Several case reports and studies with small numbers of UES patients have been published, but the diagnostic criteria for the expression of biomarkers have been inconsistent and UES was reported as just a subtype of the sarcoma cohort [10,[12][13][14][15][16][17][18][19][20][21] ( Table 5 ). Therefore, we here investigated the expression of promising therapeutic targets for UES specifically with widely accepted semi-quantitative scoring criteria [10] .…”

Section: Discussionmentioning

confidence: 99%

Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma

Baek

Rhim²,

Kim³

et al. 2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: Undifferentiated endometrial sarcoma (UES) is a very rare subtype of uterine sarcoma, which has no consensus on the treatment. We investigated the expression of potential new therapeutic targets in UES to improve its aggressive clinical course and poor survival outcome. Methods: The immunohistochemical expressions of vascular endothelial growth factor (VEGF), c-KIT, c-ABL, platelet derived growth factor receptor (PDGFR), protein kinase B (AKT1), mammalian target of rapamycin, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER2), Wilms tumor (WT1), aromatase inhibitor (CYP19A1), and histone deacetylase (HDAC) series in 10 UES patients were assessed using tissue microarrays. Results: Strongly positive immunoreactivities were observed for VEGF, AKT1, and HDAC2/7 in 8 (80.0%) tumors; for CYP19A1 and HDAC6 in 9 (90%) tumors; and for HDAC1/4/8 in 10 (100%) tumors. Strong expression of CYP19A1 and HDAC6 was associated with distant recurrence (p = 0.030, both), and expression of WT1 indicated a more advanced stage (p = 0.033). UES treated with adjuvant therapy showed better disease-free and overall survivals (both 0 vs. 33.3%, p = 0.003). Conclusion: VEGF, AKT1, CYP19A1, and the HDAC1/2/4/6/7/8 series show an especially high frequency of strong immunoreactivity in UES and can be considered potential therapeutic targets.

show abstract

“…To improve the prognosis of human uterine LMS, research is being performed to determine the role of pro-and anti-oncogenic factors that play an important function in human uterine LMS pathogenesis and could serve as molecular targets for tumour treatment. To this end, several research facilities have conducted cDNA microarray procedures with human uterine LMS and normal myometrium, showing that several known pro-oncogenic factors, as well as other factors such as brainspecific polypeptide PEP-19, the transmembrane tyrosine kinase receptor, C-KIT and mutations in fumarate hydratase, may be associated with the pathogenesis of human uterine LMS (69)(70)(71). However, in terms of LMS tumourigenesis, merely comparing the expression of potential pro-oncogenic factors between normal and malignant tissues is not sufficient because the results obtained may be the consequence of malignant transformation, not necessarily its cause.…”

Section: Future Directionsmentioning

confidence: 99%

Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma

Hayashi

Kawano

Ichimura

et al. 2016

View full text Add to dashboard Cite

Abstract. Patients with uterine leiomyosarcoma (LMS)typicallyUterine mesenchymal tumours have been traditionally divided into benign leiomyomas (LMA) and malignant leiomyosarcomas (LMS), based on cytological atypia, mitotic activity, and other criteria. Globally, uterine LMSs, which are some of the most common neoplasms in the female genital tract, are relatively rare mesenchymal tumours, having an estimated annual incidence of approximately one per 160,000 women (1). They account for approximately one-third of uterine sarcomas and 1.3% of all uterine malignancies, and are considered aggressive malignancies, with a 5-year survival rate of only 50% for patients with tumours confined to the uterus (2, 3). It is noteworthy that when adjusting for 4997 This article is freely accessible online.

show abstract

The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus

Cited by 78 publications

References 25 publications

c-Kit Expression in Patients with Uterine Leiomyosarcomas

c-Kit Expression in Patients with Uterine Leiomyosarcomas

Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma

Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma

Contact Info

Product

Resources

About